Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Chemo in 1L Non-Squamous NSCLC (Bridging Study)
NCT05841472Phase 2Recruiting
- Sponsor
- Crystal Genomics
- Start
- Aug 2023
- Primary completion
- Aug 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Crystal Genomics. Started Aug 2023; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT05841472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05841472.